PRELUDE-BTK results confirm Serranator device novel mechanism of action
Ngày 03/02/1988 12:31 | Lượt xem: 144

Cagent Vascular announced the results of its PRELUDE-BTK study at LINC 2021 (25–29 January, online). The PRELUDE-BTK study was a prospective, single-arm, multicentre feasibility study to show the safety and efficacy of serration angioplasty.

The study was led by co-principal investigators, Andrew Holden (Auckland City Hospital, Auckland, New Zealand), who presented the data, and Michael Lichtenberg (Karolinen Hospital, Arnsberg, Germany). Four other centres from Europe participated in the trial which included 30-day and six-month follow-up.

According to a Cagent Vascular press release, the Serranator percutaneous transluminal angioplasty (PTA) serration balloon catheter is the first and only angioplasty balloon cleared by the US Food and Drug Administration (FDA) and CE marked that embeds serration technology into a semi-compliant balloon for treating peripheral arterial sisease (PAD). The device is designed to create multiple longitudinal lines of interrupted micro-serrations to aid arterial expansion.

Forty-six subjects were treated with the Serranator device and 53 lesions were analysed by the core lab. The average final residual stenosis was 21.8%, with an average below-the-knee (BTK) arterial lumen gain of 1.55mm. These results were achieved with a low average maximum atmospheric pressure of six atmospheres. The bailout stent rate was 1.9%. A subset of lesions (n=10) were imaged with optical coherence tomography (OCT) and intravascular ultrasound (IVUS) and analysed by a core lab. All showed a serration effect. At 30 days, the freedom from primary safety events was 95.7%. The freedom from clinically-driven target lesion revascularisation (CD-TLR) was 97.7% with 70% of subjects achieving one or more Rutherford clinical category (RCC) improvement at six months. There were no serious adverse events related to the device.

“Today, we have insufficient data for effective lesion revascularisation in BTK arteries. Based on published plain balloon angioplasty data, especially in calcified lesions, more than 40% of the cases result in complex dissections and significant recoil phenomenon. This ultimately leads to scaffold implantation to stabilise the lumen and prevent diminished outflow. This revascularisation strategy is associated with poor patency outcomes,” stated Lichtenberg.

“The PRELUDE study clearly proved the hypothesis, that haemodynamic and morphologic success in BTK revascularisation is strongly associated with vessel compliance improvement. We need to concentrate first on this aspect, before we can discuss the need for longer-term restenosis prevention with antiproliferative substances. We know that dissections are directly associated with loss of patency and impaired wound healing. Prevention of dissections within a rigid, non-compliant vessel, along with luminal gain can only be successful with a vessel wall modification device that applies low atmospheres. The PRELUDE-BTK study clearly showed that the mechanism of action works well enough that it does not even need additional antiproliferative treatment, as CD-TLR was only 2.3% after six months,” continued Lichtenberg.

The Serranator product offering for the infrapopliteal indication is available in 2.5, 3, and 3.5mm balloon diameters and 40, 80, and 120mm balloon lengths. The company has initiated US and EU sales and plans to expand its commercial efforts later this year.

Source VascularNews

Duc Tin Clinic

 

Print Chia sẽ qua facebook bài: PRELUDE-BTK results confirm Serranator device novel mechanism of action Chia sẽ qua google bài: PRELUDE-BTK results confirm Serranator device novel mechanism of action Chia sẽ qua twitter bài: PRELUDE-BTK results confirm Serranator device novel mechanism of action Chia sẽ qua MySpace bài: PRELUDE-BTK results confirm Serranator device novel mechanism of action Chia sẽ qua LinkedIn bài: PRELUDE-BTK results confirm Serranator device novel mechanism of action Chia sẽ qua stumbleupon bài: PRELUDE-BTK results confirm Serranator device novel mechanism of action Chia sẽ qua icio bài: PRELUDE-BTK results confirm Serranator device novel mechanism of action Chia sẽ qua digg bài: PRELUDE-BTK results confirm Serranator device novel mechanism of action Chia sẽ qua yahoo bài: PRELUDE-BTK results confirm Serranator device novel mechanism of action Chia sẽ qua yahoo bài: PRELUDE-BTK results confirm Serranator device novel mechanism of action Chia sẽ qua yahoo bài: PRELUDE-BTK results confirm Serranator device novel mechanism of action Chia sẽ qua yahoo bài: PRELUDE-BTK results confirm Serranator device novel mechanism of action

Tin tức liên quan

CUSTOMER REVIEWS

  • I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

    I sincerely thank you !. Tel: 0938303275

  • Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

    Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

  • As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

  • The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

  • I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search
Customer support

    Phone: (028) 3981 2678
    Mobile: 0903 839 878 - 0909 384 389

TOP